<b>Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison</b>
Version 2 2025-07-11, 09:28
Version 1 2025-07-02, 11:16
media
posted on 2025-07-11, 09:28 authored by Adis journals on behalf of:, Sonja Ständer, Andreas Pinter, Firas Hougeir, Patricia Guyot, Yingxin Xu, Amy Praestgaard, Nick Freemantle, Ana B. Rossi, Gaëlle Bégo-Le-Bagousse, Zhixiao Wang, Kerry Noonan, Mike Bastian<p dir="ltr"><b>Article full text</b></p><p dir="ltr">The above infographic represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online. (see “read the peer-reviewed publication” opposite).</p>
History
Related Materials
- 1.
